Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Committed To Advancing Its Regulatory Science Capacity

Executive Summary

FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement
Advertisement

Related Content

FDA Budget Issues Creep Into Strategic Priorities
FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
Patent Filings Up As Industry Continues Investing In Nanotech Research
FDA Science Board Recommends Larger Nanotech Program Budget
FDA Science Board Recommends Larger Nanotech Program Budget
Nanotech Use Up: Undercover Nanoparticles Operating in Shampoos, Lipsticks
Advertisement
UsernamePublicRestriction

Register

RS017271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel